India Pharma Outlook Team | Wednesday, 22 July 2026
A new Weekly HIV Pill could change how people manage HIV. Gilead Sciences and Merck reported positive results from two late-stage studies.
The Weekly HIV Pill kept the virus suppressed in adults already receiving daily HIV treatment. The findings support upcoming regulatory filings. If approved, it could become the first once-weekly oral treatment for HIV.
The experimental treatment combines islatravir from Merck with lenacapavir from Gilead. It aims to reduce the burden of taking medicines every day. Millions of people living with HIV could benefit from a simpler treatment schedule.
The companies tested the combination in adults whose HIV was already controlled with daily antiretroviral therapy.
The first study showed excellent results.
The second study also met its primary goal.
The companies said the weekly treatment was non-inferior to daily therapies. This means it worked at least as well as existing treatment options.
Also Read: The Evolving Role of India as a Talent Hub for Healthcare R&D
HIV attacks the body's immune system. Without treatment, it can progress to acquired immunodeficiency syndrome, or AIDS.
Daily antiretroviral medicines have helped people live longer and healthier lives. However, taking pills every day can be difficult for some patients. A weekly treatment may improve convenience and support better treatment adherence.
The successful trial results also strengthen Gilead's HIV business. Investors are closely watching the rollout of Yeztugo, Gilead's lenacapavir brand. The company is looking to expand its HIV portfolio alongside its leading daily treatment.
The positive data also gives both companies confidence before filing for regulatory approval.
The studies found no new safety concerns during the trials.
The safety profile was similar to currently available daily HIV medicines.
The most common treatment-related side effects included:
These side effects were generally mild and matched those seen with existing HIV treatments.
Merck has also expanded its HIV portfolio this year. The U.S. Food and Drug Administration approved Idvynso, the company's once-daily HIV combination pill, in April. The approval added another treatment option for people living with HIV.
The latest Phase 3 results now bring Gilead and Merck closer to introducing a once-weekly HIV pill. If regulators approve the treatment, it could offer patients a more convenient alternative to daily medication. The development may mark an important step in the future of HIV treatment while maintaining the same level of virus suppression seen with current therapies.
